ICBC CSOP S&P NEW CHINA SECTORS ETF(03167.HK) Fell 1.99% to 64.040
Newtimespace News, as of 15:11 on May 15, ICBC CSOP S&P NEW CHINA SECTORS ETF(03167.HK) was quoted at HKD 64.040, down 1.99%. The ETF opened at HKD 64.400, with a high of HKD 64.400 and a low of HKD 63.780. The latest Net Asset Value (NAV) per unit is HKD 65.228, with a premium rate of 0.17%. The asset size is approximately HKD 515 million.
ICBC CSOP S&P NEW CHINA SECTORS ETF(03167.HK) tracks the S&P China New Economy Sector Index, which is compiled and published by S&P Dow Jones Indices. The index aims to capture the benefits of China's economic transformation. Its constituents are primarily selected from "new economy" sectors such as consumer, services, and technology. It also imposes a cap on A-share weightings to balance cross-market allocation. By assembling leading high-quality Chinese companies listed in the A-share, Hong Kong, and U.S. stock markets, it provides investors with an efficient tool to avoid traditional industries and gain deep exposure to the long-term growth drivers of the Chinese economy.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VIEWTRIX TECH (03310.HK): Initiates Proposed A-Share Listing, Appoints GF Securities as Coach
- HONGHUA GROUP (00196.HK): Subsidiary Signs Drilling Rig Sales Agreement Worth RMB 600 Million with Middle East Customer
- SSY GROUP (02005.HK): Trustee Purchases 1.2 Million Shares on Open Market
- PEGBIO CO-B (02565.HK): Enters Joint R&D Collaboration with SN BioScience for Long-Acting Metabolic Disease Peptides
- HANSOH PHARMA (03692.HK): NDA for HS-20093 in Small Cell Lung Cancer Accepted by NMPA